Related Experiment Video
Updated: Mar 6, 2026
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Somatic structural variations in pediatric brain tumors
Zhengwei Li1, Qingzeng Sun1, Yingchun Shi2
1Department of Pediatric Surgery, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Insights
Pediatric high-grade gliomas (pHGG) are distinct from adult tumors, with unique genetic drivers defining subgroups. Identifying these alterations, including structural variants, is crucial for developing targeted therapies for childhood brain tumors.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Genomics
Background:
- Pediatric brain tumors are the second most common childhood malignancy and a leading cause of cancer-related death.
- Pediatric high-grade glioma (pHGG) shares histological similarities with adult tumors but represents a distinct biological entity.
- Existing research highlights age-specific driver mutations in HGG, such as H3F3A K27M in young children and H3F3A G34R/V in adolescents.
Purpose of the Study:
- To underscore the biological distinctness of pediatric high-grade gliomas (pHGG) compared to adult counterparts.
- To emphasize the significance of identifying specific driver mutations and structural variants in pHGG.
- To highlight the urgent need for novel therapeutic strategies targeting unique molecular alterations in pediatric brain tumors.
Main Methods:
- Comparative analysis of pediatric and adult high-grade gliomas.
- Review of recent genomic sequencing initiatives to identify driver mutations.
- Examination of the role of structural variants and fusion genes in pHGG.
Main Results:
- Pediatric high-grade gliomas (pHGG) exhibit distinct copy number profiles and driver genetic alterations compared to adult HGG.
- Specific driver mutations (H3F3A K27M, H3F3A G34R/V, IDH1/2) define distinct HGG subgroups based on age.
- Structural variants (SV) leading to fusion genes are infrequent but significant in pHGG, offering potential therapeutic targets.
Conclusions:
- pHGG represents a biologically unique disease requiring tailored research and treatment approaches.
- Understanding the specific genetic landscape of pHGG, including structural variants, is critical for advancing therapeutic options.
- Targeting fusion proteins arising from structural variants in pHGG holds promise for novel treatment strategies.
Abstract:
Pediatrics brain tumors are the second most frequent malignancy in children, and the most common cause of cancer-related deaths in both the 0-14-year and the 15-24-year age group. Although, pediatrics high-grade glioma (pHGG) is a histologically similar tumor to that arising in adults, these are distinct biological diseases, differing in copy number profiles and driver genetic alterations. Recent sequencing initiatives have conclusively shown the existence of subgroups of HGG marked by distinct driver mutations, which are significantly enriched in young children (H3F3A K27M), teenagers and young adults (H3F3A G34R/V), and middle- aged adults (IDH1/2). Structural rearrangements resulting in novel fusion genes are strongly associated with cancer, and numerous examples exist in both adult and childhood malignancies. Although, only few have been described in pHGG. Structural variants (SV) frequently result in chimeric proteins targetable by novel therapeutic approaches, an outcome desperately needed in pHGG.
